Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view. A/S : 500 million confirmed / State of Nevada
O/S : Approx. 125.000.000
Free Float: unknown
Incorporated in: NV,USA
Year of Inc.: 2012
Signature Stock Transfer, Inc.
Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093
Plandai Biotechnology Names Diego Pellicer Co-Founder and CannabisPioneer Jamen Shively as Vice President of Global Marketing
Recently Appointed Board Member Joins Management Team to Oversee Branding and Product Strategy
NEW YORK, NY, Feb 20, 2014 (Menafn - Marketwired via COMTEX) --Plandai Biotechnology, Inc. (otcqb:PLPL), a producer of highlybioavailable plant extracts for industries including health,wellness, nutraceutical, and pharmaceutical, announced today thatJamen Shively, a leading voice in the burgeoning marijuana industryand recently appointed Board Member of Plandai, has been named asVice President of Global Marketing.
As VP-Global Marketing, the company released, Mr. Shively will beresponsible for building brand awareness and marketing strategy forall of Plandai's operations including the Diego Pellicer(R) medicalcannabis line as well as the Phytofare(TM) botanical extracts such asthe Green Tea Catechin Complex and the Limonoid Glycoside Complex.
Roger Duffield, Chief Executive Officer of Plandai, commented on Mr.Shively's new position within the Company, "We're excited to bringJamen fully into the Plandai fold. He did a brilliant job buildingthe Diego Pellicer brand, and we're confident that he will build onthis experience as we launch the first of our products in the comingweeks. Our goal is to become the leading name in highly bioavailablebotanical extracts for both nutraceutical and pharmaceuticalapplications. Jamen has the vision and expertise to help further ustowards that end."
Mr. Shively stated, "I could not be more pleased to come aboardPlandai, first as a Director and now as a full-time member of themanagement team. Plandai is uniquely positioned in that it has noreal direct competition -- no one else in the market is selling highbioavailability plant extracts. Consumers are starting to demand morefrom their vitamins and supplements and asking to what extent are thebillions of dollars being spent on such products actually increasinghealth and wellness. My role with Plandai, as I see it, is to educatethe consumer that they need to demand more from their supplementswhile also telling the Plandai story. We have a unique opportunitywith Plandai's technology to fundamentally change how we addresswellness, health and prevention through natural, botanicalsolutions."
He added, "I am also extremely excited about the application ofPlandai's technologies to cannabis, which I believe willrevolutionize the application of cannabis to preventive andtherapeutic health, under the Diego Pellicer brand. This is theopportunity of a lifetime for me and for my colleagues at Plandai tochange the world by improving the health and wellness of mankindthrough 100% natural plant extracts. We are unlocking the potentialof nature's plant nutrients for humans and animals alike."
Jamen Shively, age 45, has a background in engineering and marketing,with specialties in artificial intelligence, the modeling andoptimization of complex networks, and the creation and positioning ofnew categories of products and services. Jamen co-founded DiegoPellicer Inc. in 2012 and built the brand from zero to the #1 mostrecognized brand of cannabis in the world in less than one year.Prior to founding Diego Pellicer, Jamen was a Corporate StategyManager for Microsoft from 2003 to 2009, where he focused on thecreation and development of new categories of software products andonline services. Preceding his Microsoft career he headed ShivelyInternational Inc., which built and operated both cybercafes andeducational computer centers in Mexico. Just prior to founding DiegoPellicer Inc., Jamen founded and headed the online marketplace forthe specialty food industry, Findood, winning first place in theNorthwest Entrepreneur Network's First Look Forum Competition for thetop new startup in 2010. Jamen completed his undergraduate work atU.C. Berkeley in Civil Engineering, and did graduate work at M.I.T.and U.C. Berkeley in Civil Engineering and Materials Science. He is aFellow of the National Science Foundation.
February 14, 2014 09:00 ET
Marijuana Entrepreneur Jamen Shively Goes Public With Plandai Biotechnology, Inc.
NEW YORK, NY--(Marketwired - Feb 14, 2014) - If Plandaí Biotechnology (OTCQB: PLPL) investors liked the idea of Diego Pellicer co-founder Jamen Shively working with the company from the outside, then they'll love the idea that he's now on the inside of this public biotech. Jamen Shively, a former Microsoft executive turned marijuana entrepreneur, has gone public being named to the Board of Directors at Plandaí.
His experience at Microsoft alone makes this a great business move, but the media's attraction to Shively's confident approach to capturing 40 percent of the worldwide marijuana market makes his addition inside any public company a really big deal. Hopefully Plandaí is prepared for the media frenzy that is likely to occur when the national press that showed up en masse to his 2013 press conference, learns of Shively's appointment to the Board.
Plandaí recently completed a deal with Diego Pellicer, Inc. that allows it to market its Phytofare™ Cannabis extracts under the Diego Pellicer Gold brand, so it makes a lot of sense to Roger Duffield, CEO of Plandaí, to have Jamen Shively spearheading that branding process from inside the company. "Jamen brings a wealth of experience in both engineering and branding to Plandaí not to mention his bold leadership in the Cannabis field."
It's that bold leadership that makes Shively so attractive to the media and his "first to mind" approach will keep him in the headlines as the marijuana debate unfolds. With headlines like: "Ex-Microsoft Employee Is Going Big In The Marijuana Business," "Jamen Shively, Former Microsoft Manager, To Launch 'Premium Marijuana' Business In Washington," and "Ex-Microsoftie Jamen Shively Is Building A Marijuana Empire," Shively is clearly proving his point.
The man some are calling the "Bill Gates of Cannabis" has the attention of the media and can likely command a microphone or writer just about any time he wants. For Plandaí and its investors, Shively's not a bad guy to have around your public company, especially in a burgeoning market.
And, this is exactly what Duffield understands as his company looks to move into production and sales of its Cannabis extracts. The CEO said, "As a member of Plandaí's Board, Jamen will be instrumental in helping shape our corporate policy and direction as we move from being a research company into production and sales in the coming months."
For press releases please visit: www.plandaibiotech.com/press-release.html
_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________ Management Team
President, Chief Executive officer and member of the Board of Directors
Vice-President and Global Director: Marketing
Chief Financial Officer and member of the Board of Directors
Investor Relations and member of the Board of Directors
Address: 2226 Eastlake Ave E, #156
Seattle, Washington, 98102, USA
Phone: (425) 466-0212
Website: http://www.plandaibiotech.com Email: Info@plandaibiotech.com
LIST OF RESEARCHES, COVERAGE, ETC. : http://www.cpreports.com/2013/05/22/ray-dirks-research-plandai-biotechnology-plpl-may-23-2013-by-ray-dirks/
............................... " Ray Dirks Research is projecting price targets for Plandaí Biotechnology, Inc. of $1.00 for the Short Term (6 to 9 Months) and $3.00 for the Long Term (1 to 3 Years)." http://www.goldmanresearch.com/Search.html?ordering=&searchphrase=all&searchword=plandai ................................ "As commercialization and further testing occurs, the shares should approach the $2.00 level in 2013." http://www.otcjournal.com ..................".....I've always had a 2013 price target on PLPL of $1.00. Based on the last 10 days, it looks like I'll be right on this one. I hope you own PLPL."
PLANDAI BIOTECHNOLOGY at Africa